These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36078082)

  • 1. miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
    de la Cruz-Ojeda P; Schmid T; Boix L; Moreno M; Sapena V; Praena-Fernández JM; Castell FJ; Falcón-Pérez JM; Reig M; Brüne B; Gómez-Bravo MA; Giráldez Á; Bruix J; Ferrer MT; Muntané J
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNome Profiling Analysis Reveals Novel Hepatocellular Carcinoma Diagnostic, Prognostic and Treatment-Related Candidate Biomarkers: Post hoc Analysis of SORAMIC Trial.
    Morkunas E; Vaitkeviciute E; Inciuraite R; Kupcinskas J; Link A; Skieceviciene J; Alunni-Fabbroni M; Schütte K; Malfertheiner P; Varkalaite G; Ricke J
    Dig Dis; 2024; 42(4):336-348. PubMed ID: 38657585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
    Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.
    Shao YY; Chen PS; Lin LI; Lee BS; Ling A; Cheng AL; Hsu C; Ou DL
    Br J Cancer; 2022 Jun; 126(12):1806-1814. PubMed ID: 35236936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
    Zhang Y; Pan Q; Shao Z
    Hum Cell; 2023 Jan; 36(1):296-311. PubMed ID: 36424471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1.
    Li Y; Bai W; Zhang J
    Biomed Pharmacother; 2017 Aug; 92():1038-1044. PubMed ID: 28609841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M2 macrophage exosomes promote resistance to sorafenib in hepatocellular carcinoma cells via miR-200c-3p.
    Li W; Zhao B; Wang Q; Lu J; Wu X; Chen X
    Int Immunopharmacol; 2024 Sep; 139():112807. PubMed ID: 39068757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
    Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
    Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
    Li H; Gai L; Wu Z; Li F
    Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
    Vaira V; Roncalli M; Carnaghi C; Faversani A; Maggioni M; Augello C; Rimassa L; Pressiani T; Spagnuolo G; Di Tommaso L; Fagiuoli S; Rota Caremoli E; Barberis M; Labianca R; Santoro A; Bosari S
    Liver Int; 2015 Mar; 35(3):1077-86. PubMed ID: 25040368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
    Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
    J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
    Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Yoon EL; Yeon JE; Ko E; Lee HJ; Je JH; Yoo YJ; Kang SH; Suh SJ; Kim JH; Seo YS; Yim HJ; Byun KS
    J Korean Med Sci; 2017 Feb; 32(2):212-220. PubMed ID: 28049231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
    Zhang K; Chen J; Zhou H; Chen Y; Zhi Y; Zhang B; Chen L; Chu X; Wang R; Zhang C
    Cell Death Dis; 2018 Feb; 9(3):312. PubMed ID: 29472524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
    Lu Y; Chan YT; Wu J; Feng Z; Yuan H; Li Q; Xing T; Xu L; Zhang C; Tan HY; Lee TK; Feng Y; Wang N
    Drug Resist Updat; 2023 Nov; 71():101015. PubMed ID: 37924725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
    Guo XL; Wang HB; Yong JK; Zhong J; Li QH
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.